May 30, 2024
In recognition of Mental Health Awareness Month, discover the heartwarming world of pet therapy and learn how the De-Stress with Pups program at UC San Diego brings comfort and stress relief to members of the campus community.
March 18, 2020
New study finds gene therapy improved cardiac, muscle and liver function in Danon disease mouse models.
December 15, 2011
The Joint Commission (TJC) has approved UC San Diego Health System’s Disease-Specific Care (DSC) Certification for Ventricular Assist Device (VAD). Hospitals performing VAD as a “destination therapy” (for permanent use) receive a certification of distinction and receive reimbursement from Centers for Medicare and Medicaid Services (CMS).
December 3, 2018
Following the FDA’s approval of chimeric antigen receptor (CAR) T-cell therapies for the treatment of certain types of non-Hodgkin lymphomas, UC San Diego Health was the first medical center in San Diego to be certified to offer this type of immunotherapy outside of a clinical trial.
June 7, 2023
After a three-year hiatus due to the COVID-19 pandemic, therapy dogs have returned to UC San Diego Health.
August 12, 2021
A new cancer immunotherapy pairs ultrasound with cancer-killing immune cells to destroy malignant tumors while sparing normal tissue. The approach could make chimeric antigen receptor (CAR) T-cell therapy safer and effective at treating solid tumors.
August 23, 2023
With funding from The Leona M. and Harry B. Helmsley Charitable Trust, Jeremy Pettus, MD, an associate professor of medicine and board-certified endocrinologist who specializes in treating diabetes at UC San Diego Health, is leading a study on Liver Targeted Insulin (LTI) in Type 1 diabetes.
August 27, 2015
Degenerating neurons in patients with Alzheimer’s disease (AD) measurably responded to an experimental gene therapy in which nerve growth factor (NGF) was injected into their brains, report researchers at University of California, San Diego School of Medicine in the current issue of JAMA Neurology.
October 15, 2019
UC San Diego bioengineers are a step closer to making CAR T-cell therapy safer, more precise and easy to control. They developed a system that allows them to select where and when CAR T cells get turned on so that they destroy cancer cells without harming normal cells.
August 20, 2015
An international team of scientists headed by biologists at UC San Diego has discovered that an important class of stem cells known as human “induced pluripotent stem cells,” or iPSCs, which are derived from an individual’s own cells, can be differentiated into various types of functional cells with different fates…
